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Abstract
Background—Histone deacetylase (HDAC) inhibitors are promising therapeutics for various 
forms of cardiac disease. The purpose of this study was to assess cardiac HDAC catalytic activity 
and expression in children with single ventricle heart disease of right ventricular morphology 
(SV), as well as in a rodent model of right ventricular hypertrophy (RVH).
Methods—Homogenates of RV explants from non-failing controls and SV children were assayed 
for HDAC catalytic activity and HDAC isoform expression. Postnatal 1-day old rat pups were 
placed in hypoxic conditions and echocardiographic analysis, gene expression, HDAC catalytic 
activity and isoform expression studies of the RV were performed.
Results—Class I, IIa, and IIb HDAC catalytic activity and protein expression were elevated in 
hearts of SV children. Hypoxic neonatal rats demonstrated RVH, abnormal gene expression and 
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elevated class I and class IIb HDAC catalytic activity and protein expression in the RV compared 
to control.
Conclusions—These data suggest that myocardial HDAC adaptations occur in the SV heart and 
could represent a novel therapeutic target. While further characterization of the hypoxic neonatal 
rat is needed, this animal model may be suitable for pre-clinical investigations of pediatric RV 
disease and could serve as a useful model for future mechanistic studies.
INTRODUCTION
Right ventricular hypertrophy (RVH) and pulmonary hypertension (PH) are common 
sequelae in pediatric patients with various forms of congenital heart disease. On the severe 
end of the spectrum are children with single ventricle heart disease (SV), especially those 
with a single right ventricle (RV), such as hypoplastic left heart syndrome. SV is a rare but 
important form of hypoxic congenital heart disease that is fatal without intervention(1). 
Current treatment strategies for infants born with SV include a 3-stage surgical palliation, or 
primary heart transplantation. Primary heart transplant is significantly limited by donor 
availability. Although there have been advancements in perioperative and surgical 
approaches for SV, in the largest prospective study to date, 32% of those managed with 
surgical palliation died or were transplanted prior to 1 year of age(2). While there are many 
causes of poor outcome in SV patients, systemic right ventricular dysfunction, for which 
there are no proven therapies, is a risk factor for death and listing for transplant.(3–6)
Histone deacetylases (HDACs) are epigenetic enzymes that function canonically through 
removal of acetyl groups from lysine residues within nucleosomal histone tails. The 18 
mammalian HDACs are categorized into 4 classes: class I (HDACs 1, 2, 3, 8), class II (class 
IIa: HDACs 4, 5, 7, 9; class IIb: HDACs 6, 10), class III (SIRT1-7), and class IV (HDAC11). 
Class III HDACs are also known as sirtuins and use NAD+ as a cofactor, while HDACs 1-11 
employ Zn2+ as a cofactor for catalytic activity. Class IIa HDACs are thought to be 
protective in the setting of heart failure due to their ability to bind to and inhibit the 
transcriptional activity of myocyte enhancer factor 2 (MEF2)(7). Elevated catalytic activity 
of sirtuins appears to be beneficial in failing hearts(8), whereas elevated catalytic activity of 
class I and IIb HDACs is thought to be maladaptive(9, 10).
Two HDAC inhibitors, Vorinostat (suberoylanilide hydroxamic acid, Zolinza™) and 
Romidepsin (Istodax™), are FDA-approved to treat cutaneous T-cell lymphoma. These and 
other HDAC inhibitors are currently in clinical trials, investigating efficacy in a variety of 
oncologic and non-oncologic diseases. HDAC inhibition has beneficial effects in pre-clinical 
models of adult heart failure, reducing cardiac hypertrophy(11) and fibrosis(12), and 
suppressing the fetal gene program associated with adverse cardiac remodeling(13). These 
findings suggest that HDACs could be therapeutically targeted for the treatment of adult 
human heart failure(14). However, nothing is known about the roles of HDACs in pediatric 
heart failure.
The purpose of this study was to examine the catalytic activity and protein expression of 
HDACs in pediatric SV patients with a single RV, and characterize a neonatal animal model 
with potential to elucidate molecular mechanisms controlling pathological remodeling of the 
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pediatric RV. We hypothesized that pediatric SV patients would exhibit elevated HDAC 
catalytic activity, and that hypoxia would result in elevated HDAC catalytic activity 
coincident with adverse remodeling in neonatal rat RVs.
METHODS
This study used heart tissue samples from pediatric patients (<18 years of age) that donated 
their hearts to the University of Colorado Institutional Review Board-approved pediatric 
heart tissue bank (informed consent is obtained for all patients). Patients included males and 
females of all races and ethnic background undergoing heart transplantation at Children’s 
Hospital Colorado. Nonfailing (NF) control hearts were obtained from pediatric donors (<18 
years of age) with structurally normal hearts and normal heart function whose hearts could 
not be placed for technical reasons, usually size or blood type mismatch. SV tissue was 
obtained from explanted hearts of patients with single ventricle physiology and a 
morphologic single RV. Patients with a single LV or indeterminate morphology of the single 
ventricle were excluded. All heart tissue was rapidly flash frozen in the operating room 
immediately after removal from the subject. A detailed description of patients included in 
this study is outlined in Table 1.
Histone deacetylase catalytic activity assays
Measurement of HDAC catalytic activity was performed as previously described(15). 
Reagents were purchased from indicated vendors. HDAC inhibitor, Trichostatin A (TSA; 
Sigma) diluted in dimethylsulfoxide (DMSO). Synthetic HDAC substrates: class I HDAC 
substrate (custom synthesis by Genscript), class IIa HDAC substrate (I-1985; Bachem), class 
I/IIb HDAC substrate (I-1875; Bachem). Trypsin, Triton X-100, and DMSO were obtained 
from Sigma. 7-Amino-4-methylcoumarin (AMC; Alfa Aesar).
Frozen explants from human pediatric RV were prepared in PBS (pH 7.4) containing 0.5% 
Triton X-100, 300mM NaCl and HALT™ protease/phosphatase inhibitor cocktail 
(ThermoFisher) using a Bullet Blender homogenizer (Next Advance). Protein concentrations 
were determined by BCA Protein Assay Kit (ThermoFisher). Incubation of tissue lysates 
with class selective HDAC substrates results in a cleavable AMC product. AMC 
fluorescence was measured using a BioTeK Synergy 2 plate reader, with excitation and 
emission filters of 360 nm and 460 nm. Background fluorescence from buffer blanks were 
subtracted from raw signals, and data were normalized as needed using appropriate controls.
Immunoblotting
Immunoblotting was performed as previously described(16). Briefly, pediatric human and 
neonatal rat RV homogenates were prepared and concentrations quantified as above for 
HDAC catalytic activity assay. Proteins were resolved by SDS-PAGE, transferred to 
nitrocellulose membranes (BioRad) and probed with antibodies for HDAC1 (Cell Signaling 
Technology, 5356), HDAC2 (Cell Signaling Technology, 5113), HDAC3 (Cell Signaling 
Technology, 3949), HDAC4 (Cell Signaling Technology, 5392), HDAC5 (Cell Signaling 
Technology, 2082), HDAC6 (Santa Cruz Biotechnology, 11420), HDAC7 (Cell Signaling 
Technology, 2882), calnexin (Santa Cruz Biotechnology, 11397).
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Animal model
The pediatric neonatal rat RV hypertrophy model was adapted from a previous study(17). 
Timed-pregnant E17 Sprague Dawley rats were obtained from Charles River Laboratories. 
Rat mothers birthed their litters at Denver altitude and equilibrated for one day. Post-natal 
day 1 normoxic animals were placed in a hypobaric chamber simulating sea level altitude 
(21% oxygen), while post-natal day 1 hypoxic animals were placed in a hypobaric chamber 
simulating 18,000 feet (~10% oxygen) for seven days. Neonatal rats were anesthetized with 
isoflurane and sacrificed by thoracotomy. Hearts were flushed with saline through the aorta, 
atria were removed, and right ventricles were carefully separated from left ventricle and 
septum prior to flash freezing in liquid nitrogen.
Cardiac Imaging
Echocardiographic analysis was performed on the neonatal rats using a Vevo2100 system 
equipped with a MS400 18–38 mHz transducer (VisualSonics), as previously described(9).
Real-time polymerase chain reaction
Real-time polymerase chain (RT-PCR) reactions were performed as previously 
described(18). Total RNA was extracted using a mirVana kit (Ambion, Austin, TX), RNA 
was reverse transcribed into complementary DNA using I-script (Bio-Rad, Hercules, CA), 
and Power SYBR Green PCR Master Mix was (Applied Biosystems/Life Technologies, 
Carlsbad, CA) were used in the RT-PCR reactions. Reactions were performed using the ABI 
7300 system. Primer sequences are indicated below:
ANF: Forward 5′- gcgaaggtcaagctgctt; Reverse 5′- ctgggctccaatcctgtcaat
BNP: Forward 5′- ggtgctgccccagatgatt; Reverse 5′- ggtgctgccccagatgatt
Serca2a: Forward 5′- ggccagatcgcgctaca; Reverse 5′- gggccaattagagagcaggttt
Data analysis
GraphPad Prism software was used to generate graphs and analyze data. Student’s T-test 
with Welch’s correction or ANOVA with Bonferroni’s post-test (P<0.05) was used to 
determine statistical differences between groups.
RESULTS
Patient characteristics
The age range of the NF controls was 1.4–14 years, with 17% female. The SV group was 
composed of infants less than 3 months of age, with 17% female. The indication for 
transplantation for the SV group is outlined in Table 1, and encompasses those undergoing 
primary transplant (listed for transplant shortly after birth prior to surgical palliation) and 
includes one patient that failed an attempt at interventional palliation.
Cardiac HDAC catalytic activity is increased in pediatric single-ventricle patients
Eleven zinc-dependent HDACs are grouped into four classes (Figure 1a). HDAC catalytic 
activity has yet to be quantified in the human heart. To investigate whether pediatric SV 
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patients have altered HDAC catalytic activity, RV homogenates from pediatric NF controls 
and pediatric SV patients were incubated with HDAC class-specific fluorescent substrates. A 
significant increase in class I, IIa and IIb HDAC catalytic activity was observed in RVs of 
SV patients relative to NF control RVs (Figure 1b). Class IIb HDAC catalytic activity was 
most dramatically increased (~3.5 fold), followed by a 2-fold increase in class I HDAC 
catalytic activity, and a modest, but statistically significant increase in class IIa HDAC 
catalytic activity. These observations are consistent with reported increases in HDAC 
catalytic activity in hearts of adult rats with RVH due to PH(15).
Protein expression of distinct HDAC isoforms is elevated in hearts of pediatric single-
ventricle patients
Since all classes of HDACs measured in the enzymatic assay exhibited elevated catalytic 
activity in RVs of SV patients, we investigated whether protein expression of HDACs 
belonging to class I, IIa and IIb was concomitantly augmented. Protein expression of 
HDAC1-7 was measured by immunoblotting (Figure 2a), and quantified by normalization to 
a house-keeping protein, calnexin (Figure 2b). Expression of class I HDACs -1, -2, and -3 
was elevated and reached statistical significance in SV patient RVs compared to NF controls. 
Of the class IIa HDACs, only HDAC5 expression was significantly elevated in SV patient 
RVs. Expression of class IIb HDAC6 was not increased in SV patient RVs.
Activation of cardiac HDACs in a hypoxic neonatal rat model
RVH and failure is a common phenotype in pediatric patients with PH and various 
congenital heart lesions, including SV. In an effort to re-create elements of pediatric RVH, 
neonatal rats were placed in a hypobaric chamber simulating 18,000 feet in elevation and 
10% O2 for seven days. Control animals were simultaneously housed at sea level altitude 
(21% O2) for seven days (Figure 3a). The use of neonatal rats, as opposed to mice, 
facilitated echocardiographic assessment of RV hypertrophy and pulmonary artery blood 
flow.
In response to seven days of hypobaric hypoxia, thickness of the free wall of the neonatal rat 
RV was significantly increased in both systole and diastole compared to sea level controls, 
as quantified by M-mode echocardiography (Figure 3b and 3c). Assessment of heart 
chamber remodeling by B-mode parasternal short axis evaluation demonstrated septal wall 
flattening and chamber dilation in the RVs of hypoxic neonatal rats (Figure 3b, lower 
images). Septal wall flattening occurred in 100% of the hypoxic animals.
Pulmonary artery blood flow was assessed using color Doppler and pulse-wave Doppler. 
Hypoxic neonatal rats exhibited a significant decrease in pulmonary artery acceleration time 
(PAAT) compared to sea level controls. Pulmonary valve velocity-time integral (VTI) and 
pulmonary valve peak velocity (PVPV) were also significantly decreased in hypoxic rats 
(Figure 3d – f and data not shown); PAAT, PVPV and PV VTI are well-accepted 
measurements of PH in humans(19, 20). These findings suggest that PH exists in neonatal 
rats exposed to 7 days of hypobaric hypoxia.
Morphometric analysis performed at the time of necropsy confirmed significant RV 
hypertrophy in neonatal rats exposed to hypobaric hypoxia. After 7 days of hypobaric 
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hypoxia, the ratio of RV-to-left ventricle (LV) + septum (S) was 1.5-fold higher in hypoxic 
rats compared to sea level control animals (Figure 4a).
Myocardial failure in humans is characterized by activation of a “fetal” gene program, as 
embryonically-expressed genes are reactivated(7). This gene program is indicative of 
ventricular remodeling and is typified by increases in expression of B-type natriuretic 
peptide (BNP) and atrial natriuretic peptide (ANP), and a coordinate decrease in 
sarcoplasmic reticulum calcium-ATPase 2a (SERCA2a) expression. Quantitative PCR 
revealed that ANP and BNP mRNA levels were elevated 3-fold and 5-fold, respectively, 
while SERCA2a expression was significantly attenuated in the hypoxic neonatal rat RVs 
compared to sea level control RVs (Figure 4b – d).
HDAC catalytic activity was subsequently quantified in homogenates of RVs from sea level 
and hypoxic neonatal rats. Significant increases in class I HDAC and class IIb HDAC 
catalytic activity were observed in hypertrophic RVs, which was consistent with pediatric 
SVs. However, unlike pediatric SVs, there was no difference in class IIa HDAC catalytic 
activity in hypoxic RVs (Figure 5a). Increases in class I and class IIb HDAC activity 
correlated with the abundance of HDAC1, HDAC2, HDAC3 and HDAC6 in RVs of hypoxic 
neonatal rats (Figure 5b).
Discussion
Pharmacotherapy to prevent or treat myocardial failure in patients with single-ventricle 
physiology does not exist, underscoring the need for research to define the molecular 
mechanisms of this complex congenital heart lesion(4). Treatment of adult heart failure (HF) 
has dramatically advanced over the past several decades, yet many of the drugs used to treat 
adult HF have not been proven to be beneficial in treating pediatric HF(21). Part of the 
challenge lies in the fact that pediatric HF is a much more heterogeneous disease than in 
adults, with a low incidence of ischemic disease. Pediatric HF ranges from idiopathic dilated 
cardiomyopathy (IDC), which is the leading indication for heart transplant in children, to 
single ventricle heart disease, the leading indication for transplant in infants(22). There are 
inherent differences in myocardial adaptation in pediatric versus adult HF, including altered 
gene, protein, adrenergic receptor and microRNA expression, as well as protein 
phosphorylation and enzyme activity(18, 23–25). In addition, children are a vulnerable 
population, limiting the ability to perform the invasive studies that have been so useful in 
advancing the care of adults with HF. This study was designed to characterize the 
adaptations occurring in myocardial HDACs in the pediatric SV population, and to develop 
and perform initial characterization of an animal model that could serve to facilitate future 
mechanistic studies and drug development relevant to RV remodeling in the young.
We found that the catalytic activity of class I, IIa and IIb HDACs is elevated in RVs of 
children with SV disease compared to NF controls (Figure 1b). For class I and IIa HDACs, 
enhanced catalytic activity correlated with increased levels of HDAC isoform protein 
expression (class I HDACs -1, -2 and -3; class IIa HDAC5) (Figure 2). In contrast, activation 
of class IIb HDAC activity occurred independently of altered expression of the predominant 
isoform within this class, HDAC6. In this regard, multiple post-translational mechanisms for 
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regulation of HDAC6 activity have described in non-cardiac cells. For example, 
phosphorylation of HDAC6 by glycogen synthase kinase-3β was shown to activate HDAC6 
catalytic activity in neurons(26). Elucidation of the mechanisms controlling HDAC catalytic 
activity in SV disease awaits further investigation.
The molecular mechanisms by which HDACs contribute to adult pressure overload-induced 
LV hypertrophy, myocardial interstitial fibrosis, cardiac inflammation, pulmonary 
hypertension and RV remodeling are only beginning to be understood(27–29). HDAC 
inhibition is effective in improving HF symptoms in animal models of spontaneously 
hypertensive rats(30), mouse models of myocardial infarction/ischemia-reperfusion(31) and 
an angiotensin II-infusion model of cardiac fibrosis(12). Consistent with our hypothesis, the 
class I HDAC inhibitor apicidin attenuated hypoxia-induced RVH and pulmonary vascular 
remodeling in neonatal mice(32). A recent proteomic study using 19 different HDAC 
inhibitors in three different human cell lines demonstrated the complexity of individual 
small molecule effects on the acetylome, with differential effects on the magnitude of 
acetylation signal and specific acetylation targets between compounds(33). Due to these 
findings, selection of the class of HDAC inhibitor and specific small molecule for 
therapeutic development requires careful consideration.
In combination with our previously described abnormalities in the beta-AR system(18), 
elevated HDAC catalytic activity and expression in the RVs of children with SV suggests 
that SV hearts are undergoing molecular remodeling. Consistent with these findings, 
clinically the single RV does not tolerate chronic pressure overload indefinitely, and patients 
remain at risk for the development of ventricular failure.
While prenatal models of SV exist(34–36), a postnatal animal model is not feasible due to 
complexities of maintaining the SV circulation after birth. Therefore, we developed a 
hypoxic neonatal rat model that reasonably recapitulates some of the echocardiographic and 
molecular signatures of pediatric SV. Children born with SV are hypoxic until the 3rd stage 
of surgical palliation (Fontan) is completed at 2–5 years of age and systemic afterload on the 
RV is present throughout their lifespan, with hypertrophy essentially a universal finding. 
Hypoxia in neonatal rats results in PH and RVH by echocardiographic and morphometric 
assessment, altered myocardial gene expression, with partial recapitulation of the fetal gene 
program, elevated HDAC class I and IIb activity, and elevated HDAC protein expression. 
From both a physiologic and molecular perspective, the hypoxic neonatal rat model has 
similarities to the human SV condition that support its use for future mechanistic studies of 
RV remodeling, as well as for therapeutic development. While HDAC IIa activity was not 
increased in the rat RV as it was in the pediatric SV, whether this difference is clinically 
significant is unknown. Interestingly, HDAC 4 is associated with the cardiac sarcomere and 
may play a role in regulating cardiac contractility(37), warranting future study. The use of 
echocardiography in this model not only provides translational utility, but also allows for 
longitudinal investigation. RVH and failure are not uncommon in the pediatric 
cardiovascular disease population, and this model has potential to affect a myriad of 
populations beyond SV. PH, intrinsic lung disease, various forms of biventricular congenital 
heart disease (e.g. tetralogy of Fallot, Ebstein’s anomaly) also result in pediatric RV 
remodeling and failure.
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There are important limitations to this study. The tissue bank-based aspect of this study is 
inherently cross-sectional, and proof of mechanistic associations based on our results is not 
possible. Due to the rarity of this form of congenital heart disease, and thus the limited tissue 
available for study, it is not possible for us to determine the influence of age, prior surgical 
procedures, medications, clinical status of the patient or the temporal relationship of gene 
expression changes on our findings. We recognize that we have not developed a rodent 
model of SV. However, many of the findings in this study show consistent changes in 
phenotype and molecular signatures of hypoxic neonatal rats and SV patients versus their 
respective controls. This model could be used as a platform for the study of mechanisms of 
pressure-overloaded RV failure in the young and determination of the influence of aging and 
development vs disease on myocardial adaptations.
In conclusion, though HDACs are ubiquitously expressed and are essential enzymes, HDAC 
inhibitors are surprisingly well tolerated(38–40). There is an evolving body of literature 
suggesting that HDAC-inhibition has value for the treatment of adult cardiovascular 
diseases(14). The results of this study demonstrate that HDACs are altered in the ventricle of 
young children with single ventricle heart disease. Given the challenges of studying a rare 
disease in a vulnerable population, the hypoxic neonatal rat represents a reasonable platform 
for extending pre-clinical studies to explore mechanisms of disease and investigate novel 
therapeutics, such as HDAC inhibitors, in preventing or limiting pathologic RV remodeling.
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Figure 1. 
HDAC catalytic activity is elevated in the RV of children with SV. (a) Classifications of 
zinc-dependent HDACs. (b) HDAC Catalytic Activity: RV tissue from non-failing pediatric 
and SV hearts was homogenized in a mild lysis buffer and incubated with HDAC class I, IIa, 
and IIb-specific substrates. All classes of HDACs displayed elevated catalytic activity 
relative to control. Results are displayed as the mean with standard error; N = 6 per group, 
*P<0.05 vs controls.
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Figure 2. 
HDAC protein expression is elevated in pediatric RVs from SV patients. (a) Immunoblot 
analysis was performed with the same homogenates used for the HDAC catalytic activity 
assays employing antibodies specific for class I HDACs (HDAC1-3), class IIa HDACs 
(HDAC4, 5, 7) and class IIb HDAC6. (b) Densitometry was used to quantify immunoblot 
signals; *P<0.05 vs. controls.
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Figure 3. 
Echocardiographic analyses of right ventricular hypertrophy and pulmonary hypertension in 
hypoxic neonatal rats. (a) Study design. (b) Representative M-mode and B-mode images of 
hearts from neonatal rats exposed to hypobaric hypoxia or normoxic conditions for 7 days. 
(c) RV Free Wall Thickness, Diastole: Quantitative assessment of RV free wall (RVFW) 
thickness demonstrates increased thickness in the hypoxic rats; *P<0.05 vs. controls. (d) 
Representative Doppler images of pulmonary blood flow in normoxic and hypoxic neonatal 
rats. (e) Pulmonary artery acceleration time (PAAT) is significantly decreased in the hypoxic 
neonatal rats compared to control. (f) Pulmonary valve velocity-time integral (VTI) is also 
significantly decreased in hypoxic neonatal rats compared to control. Results are displayed 
as the mean with standard error. N = 11 per condition; P<0.05 vs. controls.
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Figure 4. 
Pathological RV remodeling in neonatal rats exposed to hypoxia. (a) RV hypertrophy was 
assessed by comparing weights of RV vs. LV + septum (S). The RV/LV+septum ratio was 
higher in the hypoxic rats. (b) Atrial natriuretic peptide, (c) B-type natriuretic peptide 
(BNP), and (d) sarcoplasmic reticulum calcium ATPase 2a (Serca2a) mRNA expression was 
determined by quantitative PCR. ANP and BNP expression was increased, while Serca2a 
expression was decreased in the hypoxic animals. Results are presented as the mean with 
standard error. N = 3 (normoxia), N = 6 (hypoxia); *P<0.05 vs. control.
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Figure 5. 
Activation of HDACs during pathological RV remodeling in neonatal rats. (a) HDAC 
catalytic activity was quantified in RV homogenates from neonatal rats exposed to hypobaric 
hypoxia (N = 6) or normoxic (N = 3) conditions for 7 days. Class I and IIb activity was 
increased in the RV of the hypoxic rats. Results are displayed as the mean with standard 
error; *P<0.05 vs. normoxic controls. (b) Immunoblot analysis was performed with the same 
rat RV homogenates used for the HDAC catalytic activity assays employing antibodies 
specific for class I HDACs (HDAC1-3) and class IIb HDAC6. HDAC 1, 2, 3 and 6 protein 
expression was increased in the RV of the hypoxic rats.
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